Drug · CHEMBL962
EPOPROSTENOL SODIUM
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. EPOPROSTENOL SODIUM. Drugs and targets, record CHEMBL962. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL962
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- Epoprostenolsodium, Prostacyclin sodium salt, Sodium prostacyclin, U-53,217A, U-53217A
- ChEMBL
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| PTGIR | Prostacyclin receptor | Prostanoid IP receptor agonist | AGONIST | https://conductscience.org/library/genes/5739 |
Source ChEMBL
Diseases3
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| pulmonary arterial hypertension | Approval | DailyMed and PMDA | 4 | 1 | https://conductscience.org/library/drugs?q=MONDO_0015924 |
| idiopathic pulmonary arterial hypertension | Approval | PMDA | 1 | 0 | https://conductscience.org/library/drugs?q=MONDO_0001999 |
| pulmonary hypertension | Approval | PMDA | 1 | 0 | https://conductscience.org/library/drugs?q=MONDO_0005149 |
Source Open Targets
Trials4
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT01105091 | Epoprostenol for Injection in Pulmonary Arterial Hypertension | Phase 4 | 30 | 2012-08-23 | epoprostenol sodium | Its name | ClinicalTrials.gov |
| NCT01462565 | Study of a New Thermo Stable Formulation of Epoprostenol Sodium to Treat Pulmonary Arterial Hypertension (PAH) | Phase 4 | 16 | 2017-10-16 | epoprostenol sodium | Its name | ClinicalTrials.gov |
| NCT01105117 | Epoprostenol for Injection in Pulmonary Arterial Hypertension - Extension of AC-066A401 | Phase 4 | 2 | 2012-08-23 | epoprostenol sodium | Its name | ClinicalTrials.gov |
| NCT01014156 | Epoprostenol in Pulmonary Embolism | Phase 4 | 14 | epoprostenol sodium | Its name | ClinicalTrials.gov |
Comparisons in its trials4
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| ACT-385781A (Epoprostenol for Injection) vs Flolan® (Epoprostenol Sodium) for Injection: serious adverse events | 6 of 20 | 2 of 10 | 30 | NCT01105091 | Trial comparisons |
ACT-385781A (Epoprostenol for Injection) vs Flolan® (Epoprostenol Sodium) for Injection: Safety and Tolerability of ACT-385781A and Flolan in Injectable Prostanoid Treatment-naïve Patients With PAH - Number of Deaths | 0 of 1 | 0 of 1 | 2 | NCT01105117 | Trial comparisons |
ACT-385781A (Epoprostenol for Injection) vs Flolan® (Epoprostenol Sodium) for Injection: Safety and Tolerability of ACT-385781A and Flolan in Injectable Prostanoid Treatment-naïve Patients With Pulmonary Arterial Hypertension (PAH) - Number of Patients With Adverse Events Leading Discontinuation of Study Treatment | 0 of 1 | 0 of 1 | 2 | NCT01105117 | Trial comparisons |
| ACT-385781A (Epoprostenol for Injection) vs Flolan® (Epoprostenol Sodium) for Injection: serious adverse events | 0 of 1 | 1 of 1 | 2 | NCT01105117 | Trial comparisons |
Papers from its trials2
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL962
GET https://conductscience.org/api/drugs/v1/CHEMBL962/targets